Tocilizumab (TCZ) is an FDA approved humanized mAb for rheumatoid arthritis and cytokine release syndrome in humans (5), functioning as an interleukin-6 (IL-6) inhibitor by blocking the binding site on the IL-6 receptor (IL-6R). Here, IL6 is linked to rheumatoid arthritis.